Genus Shares Rise: Set to Exceed Expectations with Strong First Half Performance

Genus plc (LSE: GNS), a global leader in animal genetics, has announced a robust trading update for the six months ended December 31, 2025 (H1 FY26), signaling a performance significantly ahead of previous forecasts.

The company anticipates reporting a Group adjusted profit before tax of approximately £50 million in actual currency, excluding a milestone payment related to its strategic partnership with BCA. Including the BCA milestone payment, the adjusted profit before tax is expected to reach £55.6 million.

The strong performance is primarily attributed to continued positive trading within PIC, Genus's porcine genetics division, and expected results from ABS, its bovine genetics business.

Building on the momentum from the AGM trading update in November 2025, the Board now projects that the Group's full-year FY26 adjusted profit before tax, excluding the BCA milestone, will moderately exceed the upper end of current market expectations.

Genus's strategic initiatives in China are progressing rapidly. The company confirmed that regulatory approval from SASAC for its porcine joint venture in China was secured in December 2025. This approval triggers a final $7.5 million (approximately £5.6 million) milestone payment from BCA to Genus.

The company anticipates the formal establishment of the joint venture and the receipt of the milestone payment within its fiscal third quarter.

The formation of the Chinese porcine joint venture marks a significant step in Genus's global expansion strategy, solidifying its presence in a key market.

The joint venture is expected to contribute to future growth and profitability, leveraging Genus's advanced genetics technology and BCA's local market expertise. The milestone payment further bolsters Genus's financial position, providing additional resources for strategic investments and growth initiatives.

Driver Breakdown:

• PIC Strength: Continued strong performance in the porcine genetics segment drives overall profitability.
• Strategic Partnerships: The BCA joint venture in China unlocks new market opportunities and revenue streams.
• Regulatory Approvals: Securing SASAC approval validates Genus's strategic approach and facilitates expansion in China.

The interim results for the six-month period from July 1, 2025, to December 31, 2025, will be announced on February 26, 2026.